{"transactions":[{"id":804333,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-20T21:13:09.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":49960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":49960,"derivative":{"exercise_price":24.52,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":49960},"source":{"system":"sec-edgar","filing":"0001193125-26-164267","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526164267/ownership.xml","form_type":"4"}},{"id":804332,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-04-20T21:13:09.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":28895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":118410,"source":{"system":"sec-edgar","filing":"0001193125-26-164267","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526164267/ownership.xml","form_type":"4"}},{"id":865580,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T00:08:17.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":10539,"price":22.8,"value":240289.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes a total of 556 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2025 and October 31, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":89515,"source":{"system":"sec-edgar","filing":"0001193125-26-089282","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089282/ownership.xml","form_type":"4"}},{"id":865579,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T00:08:17.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":11643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics."}],"balance_after":99498,"source":{"system":"sec-edgar","filing":"0001193125-26-089282","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089282/ownership.xml","form_type":"4"}},{"id":991093,"issuer":{"id":1990,"kind":"organization","name":"Rezolute, Inc.","symbol":"RZLT"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-11-21T22:02:01.000Z","date":"2025-11-19","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options fully vest on December 1, 2026."}],"balance_after":12000,"derivative":{"exercise_price":10.16,"expiration_date":"2035-11-19","underlying":"Common Shares","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000912282-25-001286","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1509261/000091228225001286/form4.xml","form_type":"4"}},{"id":991092,"issuer":{"id":1990,"kind":"organization","name":"Rezolute, Inc.","symbol":"RZLT"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-11-21T22:02:01.000Z","date":"2025-11-19","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units which fully vest on December 1, 2026."}],"balance_after":21000,"source":{"system":"sec-edgar","filing":"0000912282-25-001286","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509261/000091228225001286/form4.xml","form_type":"4"}},{"id":1190635,"issuer":{"id":1990,"kind":"organization","name":"Rezolute, Inc.","symbol":"RZLT"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":true}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-03-26T23:37:25.000Z","date":"2025-03-25","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 1/36th monthly beginning in April 2025."}],"balance_after":60000,"derivative":{"exercise_price":2.89,"expiration_date":"2035-03-25","underlying":"Common Shares","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000912282-25-000333","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509261/000091228225000333/form4.xml","form_type":"4"}},{"id":1226907,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-05T01:06:23.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":30246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":30246,"derivative":{"exercise_price":42.92,"expiration_date":"2035-03-01","underlying":"Common Stock","underlying_shares":30246},"source":{"system":"sec-edgar","filing":"0000950170-25-032773","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025032773/ownership.xml","form_type":"4"}},{"id":1226906,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:06:23.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":15103,"price":42.1,"value":635836.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 539 shares acquired under the Company's Amended & Restated Employee Stock Purchase Plan on April 30, 2024 and October 31, 2024"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":87855,"source":{"system":"sec-edgar","filing":"0000950170-25-032773","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025032773/ownership.xml","form_type":"4"}},{"id":1226905,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:06:23.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":18443,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric."}],"balance_after":102419,"source":{"system":"sec-edgar","filing":"0000950170-25-032773","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025032773/ownership.xml","form_type":"4"}},{"id":1226904,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:06:23.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":16813,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date"}],"balance_after":83976,"source":{"system":"sec-edgar","filing":"0000950170-25-032773","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025032773/ownership.xml","form_type":"4"}},{"id":1390123,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-07T16:37:36.000Z","date":"2024-10-03","kind":"grant","planned":false,"acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on October 3, 2024. The shares underlying the option are scheduled to vest in equal monthly installments from October 3, 2024 through October 3, 2027"}],"balance_after":56000,"derivative":{"exercise_price":5.06,"expiration_date":"2034-10-02","underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0000950170-24-113249","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017024113249/ownership.xml","form_type":"4"}},{"id":1492391,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-04T22:27:58.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":17901,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":17901,"derivative":{"exercise_price":18.56,"expiration_date":"2034-05-31","underlying":"Common Stock","underlying_shares":17901},"source":{"system":"sec-edgar","filing":"0001714899-24-000134","document":"wk-form4_1717540070.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000134/wk-form4_1717540070.xml","form_type":"4"}},{"id":1492390,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T22:27:58.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":5967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 9,402 unvested RSUs."}],"balance_after":17052,"source":{"system":"sec-edgar","filing":"0001714899-24-000134","document":"wk-form4_1717540070.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000134/wk-form4_1717540070.xml","form_type":"4"}},{"id":1594515,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-06T01:08:18.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":34200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":34200,"derivative":{"exercise_price":53.69,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":34200},"source":{"system":"sec-edgar","filing":"0000950170-24-026629","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024026629/ownership.xml","form_type":"4"}},{"id":1594514,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-03-06T01:08:18.000Z","date":"2024-03-01","kind":"sale","planned":false,"acquired":false,"shares":4768,"price":53.76,"value":256327.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 293 shares acquired under the Company's Amended & Restated Employee Stock Purchase Plan on October 31, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":67163,"source":{"system":"sec-edgar","filing":"0000950170-24-026629","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024026629/ownership.xml","form_type":"4"}},{"id":1594513,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-03-06T01:08:18.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":957,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2024 upon certification of the performance metric."}],"balance_after":71638,"source":{"system":"sec-edgar","filing":"0000950170-24-026629","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024026629/ownership.xml","form_type":"4"}},{"id":1594512,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-03-06T01:08:18.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":19400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date"}],"balance_after":70681,"source":{"system":"sec-edgar","filing":"0000950170-24-026629","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024026629/ownership.xml","form_type":"4"}},{"id":1786766,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-09-06T21:51:47.000Z","date":"2023-09-05","kind":"sale","planned":false,"acquired":false,"shares":6000,"price":37.96,"value":227760.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.95 to $38.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":51281,"source":{"system":"sec-edgar","filing":"0001209191-23-048491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919123048491/doc4.xml","form_type":"4"}},{"id":1847575,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-06-21T22:17:06.000Z","date":"2023-06-19","kind":"sale","planned":false,"acquired":false,"shares":305,"price":48.2,"value":14701.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 242 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":57281,"source":{"system":"sec-edgar","filing":"0001209191-23-038885","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919123038885/doc4.xml","form_type":"4"}},{"id":1867179,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-05T22:02:12.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":12649,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":12649,"derivative":{"exercise_price":30.92,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":12649},"source":{"system":"sec-edgar","filing":"0001714899-23-000094","document":"wk-form4_1686002517.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000094/wk-form4_1686002517.xml","form_type":"4"}},{"id":1867178,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T22:02:12.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":4216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 9,368 unvested RSUs."}],"balance_after":11085,"source":{"system":"sec-edgar","filing":"0001714899-23-000094","document":"wk-form4_1686002517.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000094/wk-form4_1686002517.xml","form_type":"4"}},{"id":1971988,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-04T00:51:21.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":39400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":39400,"derivative":{"exercise_price":45.65,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":39400},"source":{"system":"sec-edgar","filing":"0001209191-23-016039","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919123016039/doc4.xml","form_type":"4"}},{"id":1971987,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-04T00:51:21.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":3664,"price":45.25,"value":165796.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 185 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2022"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":57344,"source":{"system":"sec-edgar","filing":"0001209191-23-016039","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919123016039/doc4.xml","form_type":"4"}},{"id":1971986,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-04T00:51:21.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."}],"balance_after":60823,"source":{"system":"sec-edgar","filing":"0001209191-23-016039","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919123016039/doc4.xml","form_type":"4"}},{"id":1971985,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-04T00:51:21.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":2663,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2023 upon certification of the performance metric."}],"balance_after":38823,"source":{"system":"sec-edgar","filing":"0001209191-23-016039","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919123016039/doc4.xml","form_type":"4"}},{"id":2223830,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-06-22T23:27:52.000Z","date":"2022-06-19","kind":"sale","acquired":false,"shares":295,"price":54.78,"value":16160.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 138 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2022"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":36160,"source":{"system":"sec-edgar","filing":"0001209191-22-038774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919122038774/doc4.xml","form_type":"4"}},{"id":2353065,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T23:11:16.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":24900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":24900,"derivative":{"exercise_price":67.37,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":24900},"source":{"system":"sec-edgar","filing":"0001209191-22-015830","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919122015830/doc4.xml","form_type":"4"}},{"id":2353064,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-03-03T23:11:16.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Award of RSUs under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":36317,"source":{"system":"sec-edgar","filing":"0001209191-22-015830","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919122015830/doc4.xml","form_type":"4"}},{"id":2353063,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-03-03T23:11:16.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":2713,"price":66.62,"value":180740.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."}],"balance_after":22317,"source":{"system":"sec-edgar","filing":"0001209191-22-015830","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919122015830/doc4.xml","form_type":"4"}},{"id":2410159,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-07T23:54:54.000Z","date":"2022-02-03","kind":"grant","acquired":true,"shares":20607,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option shall vest on February 3, 2023, and an additional 1/48 of the shares subject to the option vest each month thereafter, subject to the Reporting Person remaining a non-employee director of the Issuer through each such date"}],"balance_after":20607,"derivative":{"exercise_price":33.74,"expiration_date":"2032-02-03","underlying":"Common Stock","underlying_shares":20607},"source":{"system":"sec-edgar","filing":"0001714899-22-000024","document":"wf-form4_164427807583736.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000024/wf-form4_164427807583736.xml","form_type":"4"}},{"id":2410158,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-07T23:54:54.000Z","date":"2022-02-03","kind":"grant","acquired":true,"shares":6869,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F2","text":"25% of the restricted stock units shall vest on February 3, 2023 (the \"Vesting Commencement Date\") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a non-employee director of the Issuer through each such date."}],"balance_after":6869,"source":{"system":"sec-edgar","filing":"0001714899-22-000024","document":"wf-form4_164427807583736.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000024/wf-form4_164427807583736.xml","form_type":"4"}},{"id":2540352,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-18T22:58:29.000Z","date":"2021-10-14","kind":"sale","acquired":false,"shares":303,"price":81.14,"value":24585.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":25030,"source":{"system":"sec-edgar","filing":"0001209191-21-060760","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919121060760/doc4.xml","form_type":"4"}},{"id":2637856,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-07-08T15:56:34.000Z","date":"2021-07-06","kind":"sale","acquired":false,"shares":375,"price":91.53,"value":34323.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":25333,"source":{"system":"sec-edgar","filing":"0001209191-21-045972","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919121045972/doc4.xml","form_type":"4"}},{"id":2656849,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-06-23T21:55:34.000Z","date":"2021-06-21","kind":"sale","acquired":false,"shares":572,"price":94.96,"value":54317.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on the transaction date of June 21, 2021 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":25708,"source":{"system":"sec-edgar","filing":"0001209191-21-042812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919121042812/doc4.xml","form_type":"4"}},{"id":2656848,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-06-23T21:55:34.000Z","date":"2021-06-19","kind":"sale","acquired":false,"shares":437,"price":94.63,"value":41353.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."}],"balance_after":26280,"source":{"system":"sec-edgar","filing":"0001209191-21-042812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919121042812/doc4.xml","form_type":"4"}},{"id":2720555,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-05-10T22:10:37.000Z","date":"2021-05-07","kind":"sale","acquired":false,"shares":393,"price":113.67,"value":44672.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on the transaction date of May 7, 2021 on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":26717,"source":{"system":"sec-edgar","filing":"0001209191-21-031378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919121031378/doc4.xml","form_type":"4"}},{"id":2720554,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-05-10T22:10:37.000Z","date":"2021-05-06","kind":"sale","acquired":false,"shares":307,"price":113.68,"value":34899.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."}],"balance_after":27110,"source":{"system":"sec-edgar","filing":"0001209191-21-031378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919121031378/doc4.xml","form_type":"4"}},{"id":2742797,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-04-22T00:07:35.000Z","date":"2021-04-20","kind":"sale","acquired":false,"shares":396,"price":104.28,"value":41294.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":27417,"source":{"system":"sec-edgar","filing":"0001209191-21-027881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919121027881/doc4.xml","form_type":"4"}},{"id":2811742,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-04T01:42:01.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":11000,"derivative":{"exercise_price":142.47,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001209191-21-017554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919121017554/doc4.xml","form_type":"4"}},{"id":2811741,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:42:01.000Z","date":"2021-03-02","kind":"sale","acquired":false,"shares":707,"price":138.16,"value":97679.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The sales reported on this row were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":27813,"source":{"system":"sec-edgar","filing":"0001209191-21-017554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919121017554/doc4.xml","form_type":"4"}},{"id":2811740,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:42:01.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":2470,"price":138.17,"value":341279.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.16 to $138.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":28520,"source":{"system":"sec-edgar","filing":"0001209191-21-017554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919121017554/doc4.xml","form_type":"4"}},{"id":2811739,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:42:01.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":4636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents 1,530 shares of common stock and 3,106 RSUs into which previously granted performance stock units were converted on March 1, 2021 upon certification of the performance metric. The RSUs will fully vest on March 1, 2022."}],"balance_after":30990,"source":{"system":"sec-edgar","filing":"0001209191-21-017554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919121017554/doc4.xml","form_type":"4"}},{"id":2811738,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:42:01.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."}],"balance_after":26354,"source":{"system":"sec-edgar","filing":"0001209191-21-017554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919121017554/doc4.xml","form_type":"4"}},{"id":2880921,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-04T01:04:10.000Z","date":"2020-06-03","kind":"sale","acquired":false,"shares":2516,"price":74.69,"value":187920.04,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":20854,"source":{"system":"sec-edgar","filing":"0001209191-21-007555","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919121007555/doc4.xml","form_type":"4"}},{"id":3004887,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-10-16T23:20:11.000Z","date":"2020-10-14","kind":"sale","acquired":false,"shares":220,"price":88,"value":19360.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":23370,"source":{"system":"sec-edgar","filing":"0001209191-20-055176","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919120055176/doc4.xml","form_type":"4"}},{"id":3086189,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-07-08T16:29:55.000Z","date":"2020-07-06","kind":"tax_withholding","acquired":false,"shares":260,"price":86.75,"value":22555.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":23590,"source":{"system":"sec-edgar","filing":"0001209191-20-041641","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919120041641/doc4.xml","form_type":"4"}},{"id":3102837,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-06-22T17:47:09.000Z","date":"2020-06-19","kind":"tax_withholding","acquired":false,"shares":303,"price":78.22,"value":23700.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":23850,"source":{"system":"sec-edgar","filing":"0001209191-20-038111","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919120038111/doc4.xml","form_type":"4"}},{"id":3156029,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-05-09T00:11:24.000Z","date":"2020-05-06","kind":"tax_withholding","acquired":false,"shares":209,"price":66.26,"value":13848.34,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":24153,"source":{"system":"sec-edgar","filing":"0001209191-20-028117","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919120028117/doc4.xml","form_type":"4"}},{"id":3172202,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-04-21T19:31:28.000Z","date":"2020-04-19","kind":"tax_withholding","acquired":false,"shares":210,"price":58.57,"value":12299.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":24362,"source":{"system":"sec-edgar","filing":"0001209191-20-025186","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919120025186/doc4.xml","form_type":"4"}},{"id":3230979,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-04T01:02:15.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":22000,"derivative":{"exercise_price":56.08,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-20-015766","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919120015766/doc4.xml","form_type":"4"}},{"id":3230978,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-03-04T01:02:15.000Z","date":"2020-03-01","kind":"tax_withholding","acquired":false,"shares":824,"price":56.08,"value":46209.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":24572,"source":{"system":"sec-edgar","filing":"0001209191-20-015766","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919120015766/doc4.xml","form_type":"4"}},{"id":3230977,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-03-04T01:02:15.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":3287,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents 1,085 shares of common stock and 2,202 RSUs into which previously granted performance stock units were converted on March 1, 2020 upon certification of the performance metric. The RSUs will fully vest on March 1, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":25396,"source":{"system":"sec-edgar","filing":"0001209191-20-015766","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919120015766/doc4.xml","form_type":"4"}},{"id":3230976,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-03-04T01:02:15.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":22109,"source":{"system":"sec-edgar","filing":"0001209191-20-015766","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919120015766/doc4.xml","form_type":"4"}},{"id":3392723,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-10-16T23:32:59.000Z","date":"2019-10-14","kind":"grant","acquired":true,"shares":1208,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on October 14, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":14309,"source":{"system":"sec-edgar","filing":"0001209191-19-053328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919119053328/doc4.xml","form_type":"4"}},{"id":3465047,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-07-09T23:40:38.000Z","date":"2019-07-06","kind":"tax_withholding","acquired":false,"shares":260,"price":59.51,"value":15472.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":13101,"source":{"system":"sec-edgar","filing":"0001209191-19-041642","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919119041642/doc4.xml","form_type":"4"}},{"id":3480984,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-22T00:05:25.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":12000,"derivative":{"exercise_price":63.27,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-19-038667","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919119038667/doc4.xml","form_type":"4"}},{"id":3480983,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":51926,"kind":"person","name":"Harris Erik","position":1,"cik":"0001780113","reported_name":"Harris Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-06-22T00:05:25.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":13361,"source":{"system":"sec-edgar","filing":"0001209191-19-038667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919119038667/doc4.xml","form_type":"4"}}]}